Arcus Corp (RCUS) - Gross Sales Margin

Official company branding of Arcus Bio (RCUS)

The target gross margin of Arcus Biosciences, Inc. (RCUS) exhibits a trend where the value is maintained at 91.00. Profitability growth is driven by the creation of unique patents for subsequent high-value sales. Stability of these metrics is guaranteed by support from Gilead, which reduces financial risks. However, the business model relies on the full outsourcing of clinical trials and production, creating a high dependency on external contractors.

arcusbio.com (RCUS) - Gross Margin from 07/04/2022 to 11/20/2026

Analytical breakdowns and data insights for company Arcus Biosciences, Inc. (RCUS)

- stock value and consensus price forecast:
Fundamental valuation:Arcus Biosciences, Inc.
Signature product of Arcus Corp

For a fundamental valuation of Arcus Biosciences, Inc. (RCUS), it is critical to track the revenue share remaining after covering direct production costs. By analyzing the gross profit margin, an investor determines the efficiency of combined cancer immunotherapy development and the degree of cost optimization in creating synergistic drug pairs, which directly confirms the issuer's capital management quality and market resilience.